AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Vir Biotechnology Inc. (VIR)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

9.74

-0.11 (-1.12%)

At close: Feb 20, 2025, 3:59 PM

9.67

-0.77%

After-hours: Feb 20, 2025, 06:05 PM EST

undefined% (undefined)

Bid	9.46
Market Cap	1.34B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-3.93
PE Ratio (ttm)	-2.48
Forward PE	n/a
Analyst	Buy

Ask	10.08
Volume	432,872
Avg. Volume (20D)	2,136,406
Open	9.85
Previous Close	9.85
Day's Range	9.59 - 9.90
52-Week Range	6.56 - 14.45
Beta	undefined

About VIR

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus....

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Oct 11, 2019

Employees 587

Stock Exchange NASDAQ

Ticker Symbol VIR

Website https://www.vir.bio

Full Company Profile

Analyst Forecast

According to 6 analyst ratings, the average rating for VIR stock is "Buy." The 12-month stock price forecast is $20, which is an increase of 105.23% from the latest price.

Buy 83.33%

Hold 16.67%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Vir Biotechnology Inc. is scheduled to release its earnings on Feb 26, 2025, after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 month ago

+58.17%

Vir Biotechnology shares are trading higher after ... Unlock content with Pro Subscription

3 months ago

+23.63%

Vir Biotechnology shares are trading higher. The company reported Q3 financial results.

News

1 day ago · businesswire.com

Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that members of the executive team are scheduled to participate in a fireside chat at the TD Cowen 45th Annual Hea...

1 month ago · seekingalpha.com

Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025

This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 bil...

1 month ago · benzinga.com

Morgan Stanley Doubles Vir Biotechnology Price Forecast - Here's Why

On Wednesday, Vir Biotechnology, Inc. VIR presented initial Phase 1 data from two of its dual-masked T-cell engagers (TCEs): VIR-5818, which targets a variety of HER2-expressing solid tumors, and VIR...

1 month ago · zacks.com

VIR Stock Up on Early Safety & Efficacy Data on Two Cancer Candidates

Vir Biotechnology posts encouraging initial data from phase I studies evaluating VIR-5818 and VIR-5500 in heavily pretreated patients with various solid tumors.

1 month ago · seekingalpha.com

Vir Biotechnology: A Rocket Off Phase 1 Data

Vir Biotechnology's recent share price rally is driven by their promising cancer program, despite their primary focus on hepatitis management. The company's market cap has surged past $1 billion, rais...

1 month ago · benzinga.com

Vir Biotechnology Stock Soars On Prostate Cancer Trial Data - Here's Why

On Wednesday, Vir Biotechnology, Inc. VIR stock traded higher after the company presented initial Phase 1 data from two of its dual-masked T-cell engagers (TCEs): VIR-5818, which targets a variety of...

1 month ago · businesswire.com

Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today is presenting initial Phase 1 data from two of its dual-masked T-cell engagers (TCEs): VIR-5818, targeting a variety of HER2...

2 months ago · businesswire.com

Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology Inc. (NASDAQ: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan He...

2 months ago · seekingalpha.com

Vir Biotechnology Could Be An Early Riser In 2025 With Oncology Data In January

VIR's is expected to report data in January from two phase 1 trials of VIR-5500 and VIR-5818, two T-cell engagers, in various cancer types. JANX recently produced promising data with JANX007, which is...

2 months ago · businesswire.com

Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that tobevibart and elebsiran have received U.S. Food and Drug Administration (FDA) Breakthrough Therapy designati...

Load More News